Caris Life Sciences (CAI) Current Assets (2024 - 2026)

Caris Life Sciences (CAI) posted quarterly Current Assets of $1.0 billion for Q1 2026, up 1.64% quarter-over-quarter from $997.8 million in Q4 2025.

Caris Life Sciences (CAI) Current Assets (2024 - 2026) Analysis & Trends

Caris Life Sciences' Current Assets history runs 3 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

In Q1 2026, Current Assets changed N/A year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (changed N/A YoY), while the FY2025 annual figure was $997.8 million, up 362.52% from the prior year.
Current Assets for Q1 2026 stood at $1.0 billion, up from $997.8 million in the prior quarter.
The five-year high for Current Assets was $1.0 billion in Q1 2026, with the low at $215.7 million in Q4 2024.
The 3-year median for Current Assets is $854.2 million (2025), against an average of $783.1 million.
Peak annual rise in Current Assets reached 362.52% in 2025, while the deepest fall reached 362.52% in 2025.
Caris Life Sciences' Current Assets stood at $215.7 million in 2024, then jumped by 362.52% to $997.8 million in 2025, then advanced by 1.64% to $1.0 billion in 2026.
Business Quant data shows CAI's Current Assets at $1.0 billion in Q1 2026, $997.8 million in Q4 2025, and $854.2 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Assets (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	12.54 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	18.45 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	8.07 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	4.03 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	7.22 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	11.83 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	1.76 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	4.62 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	1.63 Bn
10	Caris Life Sciences	6.16 Bn	5.37 Bn	182.38 Mn	1.06 Bn

Download Data